Latest News and Press Releases

-- Transaction creates strong, diversified rare-disease focused portfolio-- Novelion Therapeutics completes concurrent financing of approximately $22 million -- Company to host conference call today...

CAMBRIDGE, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...

CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...

CAMBRIDGE, Mass., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...

CAMBRIDGE, Mass., Sept. 24, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...

CAMBRIDGE, Mass., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...

-- Company records $44.5 million in total net product sales ---- Company reiterates 2016 total net product sales guidance of between $130 and $150 million -- CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE...

CAMBRIDGE, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...

--Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development...

CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...